EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum HMGB1 and Alcohol-Related Liver Disease

Iwona Popiolek iD, Piotr Hydzik, Krzysztof Ciszowski, Barbara Balicka-Slusarczyk, Ewa Gomolka iD, Beata Szkolnicka, Lubomir Skladany, Juan Pablo Arab iD, Ivica Grgurevic, Michal Kukla

Journal of Clinical Medicine · 29.04.2026 · 15 (9) · 3397

DOI: 10.3390/jcm15093397 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 29.04.2026. Verfasst von Iwona Popiolek und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Toxicology and Environmental Diseases, Jagiellonian University Medical College, Botaniczna 3, 31-503 Kraków, Poland. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jagiellonian University Medical College, Jagiellonian University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Alcohol-related liver disease (ALD) lacks widely adopted biomarkers that reflect disease activity and severity. High-mobility group box 1 (HMGB1), a damage-associated molecular pattern, has been implicated in ALD pathogenesis. We evaluated the detectability of circulating HMGB1 in patients with ALD during active alcohol use and examined clinical associations.

Methods

In this observational study, we enrolled hospitalized adults with ongoing ethanol use between 1 November 2023, and 31 December 2024. Controls had no history of excessive alcohol consumption and normal liver biochemistry. Clinical features, laboratory tests, and severity scores (including MELD, MELD-Na, and CLIF-C AD) were recorded. Serum HMGB1 was measured by ELISA; values ≥ 0.08 ng/mL were considered detectable.

Results

The cohort included 68 participants (58 with ALD and 10 controls); 29 patients had cirrhosis. HMGB1 was detectable in 32 measurements (42%), with a median concentration of 4.6 ng/mL (IQR, 0.78–10.6; range, 0.08–140.6). Detectable HMGB1 was more frequent in ALD than in controls (47% vs. 11%). Compared with HMGB1-negative patients, HMGB1-positive patients had higher total bilirubin and creatinine levels, prolonged activated partial thromboplastin time, higher white cell counts, and lower serum sodium. Liver enzyme activities and INR did not differ meaningfully by HMGB1 status. MELD, MELD-Na, and CLIF-C AD scores were higher in HMGB1-positive patients. Admission ethanol levels were higher in HMGB1-negative patients. Mortality and readmission did not differ by HMGB1 status.

Conclusions

Detectable circulating HMGB1 is present in a subset of patients with ALD and is associated with greater liver disease severity.

Schlagwörter

Stichwörter der Autor:innen

HMGB1alcohol hepatitisalcohol use disorderalcohol-related liver disease

Autor:innen und Institutionen

  • Department of Toxicology and Environmental Diseases, Jagiellonian University Medical College, Botaniczna 3, 31-503 Kraków, Poland.
  • Gastroenterology, Hepatology, Toxicology and Internal Medicine Clinical Department, University Hospital in Kraków, Jakubowskiego 2, 30-688 Kraków, Poland.
  • Toxicological Laboratory, Diagnostics Department, University Hospital in Kraków, Jakubowskiego 2, 30-688 Kraków, Poland.
  • Division Hepatology, Gastroenterology and Liver Transplantation, 2nd Department of Internal Medicine, Faculty of Medicine, Slovak Medical University, F. D. Roosevelt Teaching Hospital, 975 17 Banska Bystrica, Slovakia.
  • Departamento de Gastroenterología, Escuela De Medicina, Pontificia Universidad Católica De Chile, Santiago 8320165, Chile.
  • Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA.

ORCID-Profile: Iwona Popiolek, Ewa Gomolka, Juan Pablo Arab

Förderung

  • Jagiellonian University Medical College
  • Jagiellonian University

Zitieren

APA

Popiolek, I., Hydzik, P., Ciszowski, K., Balicka-Slusarczyk, B., Gomolka, E., Szkolnicka, B., Skladany, L., Arab, J. P., Grgurevic, I., & Kukla, M. (2026). Serum HMGB1 and Alcohol-Related Liver Disease. Journal of Clinical Medicine, 15(9), 3397. https://doi.org/10.3390/jcm15093397

Vancouver

Popiolek I, Hydzik P, Ciszowski K, Balicka-Slusarczyk B, Gomolka E, Szkolnicka B, et al. Serum HMGB1 and Alcohol-Related Liver Disease. Journal of Clinical Medicine. 2026;15(9):3397. doi:10.3390/jcm15093397

BibTeX
@article{Popiolek2026,
  author = {Popiolek, Iwona and Hydzik, Piotr and Ciszowski, Krzysztof and Balicka-Slusarczyk, Barbara and Gomolka, Ewa and Szkolnicka, Beata and Skladany, Lubomir and Arab, Juan Pablo and Grgurevic, Ivica and Kukla, Michal},
  title = {Serum HMGB1 and Alcohol-Related Liver Disease},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {9},
  pages = {3397},
  doi = {10.3390/jcm15093397}
}
Kostenlos starten →